Xbrane Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	66.75	86.59	124.33	65.4	193.99	295.18
Cash & Short-Term Investments	66.75	86.59	124.33	65.4	193.99	295.18
Cash Growth	170.13%	-30.36%	90.10%	-66.29%	-34.28%	21.40%
Accounts Receivable	19.45	6.74	16.85	-	1.34	-
Other Receivables	8.63	5.56	16.97	34.21	46.12	50.25
Total Trade Receivables	28.08	12.3	33.83	34.21	47.46	50.25
Inventory	199.4	194.27	246.9	106.86	50.26	-
Other Current Assets	71.44	81.97	200.84	255.22	221.81	215.58
Total Current Assets	365.67	375.13	605.9	461.69	513.52	561.01
Net Property, Plant & Equipment	0.01	0.04	23.86	88.2	71.05	73.8
Other Intangible Assets	305.08	296.46	167.69	99.67	102	49.67
Other Long-Term Assets	-	-	41.04	3.95	3.95	3.95
Total Assets	670.76	671.62	842.43	653.51	690.52	688.43
Accounts Payable	29.03	8.96	242.57	30.97	23.3	41.39
Accrued Expenses	33.33	36.19	188.45	216.3	200.24	159.36
Current Portion of Long-Term Debt	56.88	-	82.5	62.5	-	-
Current Portion of Leases	-	-	13.27	13.37	9.16	7.91
Other Current Liabilities	1.37	7.52	11.16	3.42	3.87	11.01
Total Current Liabilities	120.6	52.66	537.94	326.56	236.57	219.67
Long-Term Debt	-	58.31	66.37	112.9	-	-
Long-Term Leases	-	-	29.58	42.71	29.06	36.48
Other Long-Term Liabilities	-	-	-	0.01	-	0.54
Total Long-Term Liabilities	-	58.31	95.95	155.62	29.06	37.02
Total Liabilities	120.6	110.97	633.89	482.17	265.63	256.69
Common Stock	2.06	2.06	343.5	6.68	6.17	5.61
Additional Paid-in Capital	1,389	1,386	1,395	1,429	1,294	1,134
Accumulated Other Comprehensive Income	10.13	10.11	10.23	10.12	10.32	5.17
Retained Earnings	-850.68	-837.61	-1,540	-1,274	-885.83	-713.31
Shareholders' Equity	550.16	560.65	208.54	171.34	424.89	431.74
Total Liabilities & Equity	670.76	671.62	842.43	653.51	690.52	688.43
Total Debt	56.88	58.31	191.72	231.48	38.22	44.38
Net Cash (Debt)	9.87	28.28	-67.39	-166.08	155.77	250.8
Net Cash Growth	-	-	-	-	-37.89%	5.88%
Net Cash Per Share	0.01	1.72	-4.10	-35.06	761.51	1328.77
Book Value	550.16	560.65	208.54	171.34	424.89	431.74
Book Value Per Share	0.48	34.11	12.69	36.17	2077.09	2287.41
Tangible Book Value	245.08	264.19	40.85	71.67	322.89	382.07
Tangible Book Value Per Share	0.21	16.08	2.49	15.13	1578.48	2024.25